An established drug for recurrent multiple myeloma might effectively be repurposed to improve the survival and day-to-day lives of patients with devastating sickle cell disease, according to revealing new research by a Feinstein Institute for Medical Research scientist.
The study, by Lionel Blanc, PhD, an assistant investigator at the Feinstein Institute, will be published Dec. 17 in the journal Blood. Dr. Blanc’s research, performed in collaboration with the New York Blood Center, Yale School of Medicine and University of Montpellier in France, was the first to identify how the drug pomalidomide increases production of fetal hemoglobin, known to interfere with the so-called “sickling” of red blood cells implicated in sickle cell disease (SCD).
Illuminating pomalidomide’s mechanism of action offers proof of concept that the US Food and Drug Administration (FDA)-approved medication could potentially be used to treat SCD, representing better outcomes compared to current drug treatment for the 100,000 Americans with SCD, an inherited disorder causing poor oxygen delivery, organ damage and even death.
“We knew the drug would make fetal hemoglobin, but we didn’t know to what extent or how. That was the goal of the study,” explained Dr. Blanc, also an assistant professor of molecular medicine and pediatrics at Hofstra North Shore-LIJ School of Medicine and an Allied World St. Baldrick’s Scholar.
“We can also say something else – that hydroxyurea, the only FDA-approved drug for sickle cell anemia, was less effective than pomalidomide and appeared to act through a different mechanism of action,” he added. “The current therapy is good, but not everyone responds equally to hydroxyurea, and what we hope with pomalidomide is to improve this.”
Pomalidomide, a derivative of thalidomide used in advanced cases of the cancer multiple myeloma, works by killing malignant plasma cells. But Dr. Blanc and his colleagues demonstrated in the new research, performed on stem cells taken from five SCD patients and 120 normal controls, how pomalidomide also generated fetal hemoglobin, the fetal version of the protein in red blood cells that carries oxygen to body tissues.
In patients with congenital conditions producing anemia such as SCD and beta-thalassemia, fetal hemoglobin is normal, but adult hemoglobin – produced after birth – is abnormal. Therefore, reversing their production of adult hemoglobin back to fetal hemoglobin can reverse the course of their disease.
In addition to the 100,000 US residents with SCD, the condition also affects millions globally. “I would remind people that anemia impacts 1.6 billion people worldwide, making it a global economic burden,” Dr. Blanc notes.
Dr. Blanc and his colleagues in the Division of Hematology/Oncology at Cohen Children’s Medical Center of New York plan to launch a clinical trial in the near future in collaboration with other institutions to test pomalidomide, which is taken orally, in young adults with SCD.
Currently, the only potential cures for SCD are gene therapy, still in the experimental stage, or stem cell transplant, but these resource-intense treatments aren’t available to the vast majority of patients, particularly in the developing world.
“Our hope is to alleviate the symptoms of sickle cell disease by using a pill that could be made available to almost all patients, worldwide,” Dr. Blanc said.
The Latest on: Sickle Cell Disease
via Google News
The Latest on: Sickle Cell Disease
- Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Diseaseon December 7, 2021 at 5:13 am
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today ...
- Girl with sickle cell disease had a wish to be on a billboard. She and her twin now smile at passing cars in Marylandon December 6, 2021 at 1:10 pm
Abigail Makanjuola is a self-proclaimed fashionista. And at only 4 years old, she's already on a billboard. Wearing matching red dresses, Abigail (who goes by Abi) and her twin sister, Valerie (who ...
- Kisumu to launch sickle cell management uniton December 6, 2021 at 8:55 am
A sickle cell disease management and care project is set to be launched on Tuesday at the Jaramogi Oginga Odinga Teaching and Referral Hospital. This will aid in responding to the high burden of the ...
- Protecting the brain in sickle cell anemia: the value of beginning early in lifeon December 6, 2021 at 7:05 am
A recently published article in (Volume 246, Issue 23, December, 2021) highlights the importance of early-in-life screening for brain damage in children with sickle cell. The study, led by Dr. Jane ...
- Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease Treatmenton December 6, 2021 at 6:51 am
Fulcrum Therapeutics Inc (NASDAQ:FULC) has announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 trial of FTX-6058 for sickle cell disea ...
- Fulcrum Therapeutics Up After Data on FTX-6058 for Sickle Cell Diseaseon December 6, 2021 at 5:22 am
By Michael Dabaie Fulcrum Therapeutics Inc. shares were up 7%, to $15, in premarket trade after the clinical-stage biopharmaceutical company said it ...
- Girl with sickle cell disease had a wish to be on a billboard. She and her twin now smile at passing cars in Md.on December 6, 2021 at 3:49 am
And at only 4 years old, she’s already on a billboard. Wearing matching red dresses, Abigail (who goes by Abi) and her twin sister, Valerie (who goes by Vivi), are pictured on a Macy’s billboard in ...
- Lack of blood donations affects a Columbus woman with Sickle Cell Diseaseon December 3, 2021 at 8:55 am
Since the start of the pandemic, a Columbus woman has had to struggle with her Sickle Cell Disease even more due to a lack of blood donations. Alexis Lott has been ...
- GBT Supports the ASH Research Collaborative's Data Hub Sickle Cell Disease Programon December 2, 2021 at 4:00 am
The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of Hematology (ASH), and ...
- Global Sickle Cell Disease Pipeline Drugs and Companies Report 2021 - ResearchAndMarkets.comon December 2, 2021 at 2:15 am
Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials" report has been added to ResearchAndMarkets.com's offering.
via Bing News